- Previous Close
8.00 - Open
8.00 - Bid 7.00 x --
- Ask 9.00 x --
- Day's Range
8.00 - 8.20 - 52 Week Range
5.00 - 30.90 - Volume
2,592 - Avg. Volume
23,134 - Market Cap (intraday)
2.614M - Beta (5Y Monthly) 0.66
- PE Ratio (TTM)
0.01 - EPS (TTM)
8.22 - Earnings Date May 8, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 1, 2023
- 1y Target Est
--
CRISM Therapeutics Corporation focuses on drug delivery technology to improve the clinical performance of cancer drugs as treatments for solid tumors. Its lead product, ChemoSeed that can be implanted directly into a tumor or the resection margin following the removal of a tumor, ensuring effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. Its ChemoSeed used for treatment of gliomas, a brain tumor. The company was founded in 2016 and is based in Road Town, the British Virgin Islands.
www.crismtherapeutics.comRecent News: CRTX.L
View MorePerformance Overview: CRTX.L
Trailing total returns as of 2/14/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRTX.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRTX.L
View MoreValuation Measures
Market Cap
2.61M
Enterprise Value
752.25k
Trailing P/E
0.01
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.26
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.66%
Return on Equity (ttm)
-62.45%
Revenue (ttm)
-31k
Net Income Avi to Common (ttm)
-1.77M
Diluted EPS (ttm)
8.22
Balance Sheet and Cash Flow
Total Cash (mrq)
1.86M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.42M